"selective primary health care" - Google News

[unable to retrieve full-text content]

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)  Novartis

Comments

Popular posts from this blog

8 Ways to Get Care When There Are No Primary Care Doctors - U.S. News & World Report

Vaccines Offer Protection Against Cold and Cough Symptoms - Pharmacy Times